Trial Profile
Prospective pivotal study of AADC gene therapy (AAV-hAADC gene therapy) in patients with aromatic L-amino acid decarboxylase (AADC) deficiency
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2018
Price :
$35
*
At a glance
- Drugs Eladocagene exuparvovec (Primary)
- Indications Aromatic amino acid decarboxylase deficiency; Inborn error amino acid metabolic disorders
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2016 According to an Agilis Biotherapeutics media release, this pivotal study in anticipated to begin in 2017.
- 02 Mar 2016 New trial record